Document is current
Any future updates will be listed below
-
Authors
Pan, Sixuan https://orcid.org/0009-0001-3795-4903
Fernández-Maestre, Inés
Chang, Kai-Chun https://orcid.org/0000-0001-7200-3532
Van Haver, Stéphane
Wereski, Matthew G.
Haugh, Alexandra M.
Tsai, Katy K.
Daud, Adil I. https://orcid.org/0000-0002-6617-8421
Bowman, Robert L. https://orcid.org/0000-0002-8294-8748
Vasudevan, Harish N. https://orcid.org/0000-0001-9633-1100
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Abate, Adam R. https://orcid.org/0000-0001-9614-4831
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01NS130876)
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 19 December 2025
First Online: 21 January 2026
Competing interests
: R.L.L. is on the Supervisory board of Qiagen (compensation/equity), a co-founder/board member at Ajax (equity), and is a scientific advisor to Mission Bio, Syndax, Scorpion, Zentalis, Auron, Prelude, and C4 Therapeutics; for each of these entities, he receives equity/compensation. He has received research support from the Cure Breast Cancer Foundation, Calico, Zentalis and Ajax, and has consulted for Jubilant, Goldman Sachs, Incyte, AstraZeneca and Janssen. The remaining authors declare no competing interests.
